Avalo Therapeutics, Inc. · NASDAQ:AVTX
Orbimed Advisors LLC reported a 6.40% stake in Avalo Therapeutics, Inc. (Schedule 13G/A)
Event Dec 31, 2025 · Filed Feb 17, 2026
Orbimed Advisors LLC reported a 6.40% stake in Avalo Therapeutics, Inc., 1,187,300 shares, as a passive investor on Dec 31, 2025. Filed Feb 17, 2026 (Schedule 13G/A).
- Stake
- 6.40%
- Shares
- 1,187,300
- Intent
- Passive
- What changed
- Stake changed
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| OrbiMed Advisors LLC | 6.40% | 1,187,300 |
Source
Related
- Avalo Therapeutics, Inc.
- Orbimed Advisors LLC
- Avalo Therapeutics, Inc. shareholders
- Schedule 13G/A · Orbimed Advisors LLC · May 15, 2026
- Schedule 13G/A · Orbimed Advisors LLC · Aug 14, 2025
- Form 4 · Sullivan Christopher Ryan · Sep 18, 2026
- Form 4 · Sullivan Christopher Ryan · Sep 11, 2026
- Form 4 · Doyle Mittie · Sep 1, 2026
- Form 4 · Sullivan Christopher Ryan · Aug 19, 2026
- Form 4 · Doyle Mittie · Aug 19, 2026